

January 12, 2023  
Fuji Pharma Co., Ltd.

## **New Agreement with Alvotech on Biosimilar Development and Marketing in Japan**

Fuji hereby announced today that Fuji and Alvotech (Head office: Iceland) have decided to expand their existing exclusive commercialization partnership covering Japan, by adding a new biosimilar candidate

On November 16, 2018, Fuji and Alvotech announced “[ALVOTECH AND FUJI PHARMA ENTER INTO EXCLUSIVE PARTNERSHIP FOR DEVELOPMENT AND COMMERCIALIZATION OF BIOSIMILARS IN JAPAN](#)”, and on October 17, 2022, Fuji and Alvotech announced “Submission of a Marketing Approval Application for the 1st Biosimilar Product Developed under Alvotech Partnership”. Fuji and Alvotech agreed on an exclusive partnership for development and commercialization of biosimilars in Japan.

The binding term sheet further strengthens biosimilar development and commercialization in Japan, enabling Fuji to enter into new therapeutic areas. This agreement brings to six the total number of products for which terms have been agreed upon between Fuji and Alvotech.

In our Mid-Term Business Plan (FY9/2020-9/2024), we have set the goal of becoming the No.1 biosimilar manufacturer in Japan by the FY9/2029. Fuji will expand biosimilar lineups to deliver high quality biosimilar products to Japanese market and contribute to patients, medical fields and medical economics.

### **For further information, contact**

Fuji Pharma Co., Ltd.

Corporate Communication Section, Corporate Planning Department, Corporate Strategy Division

[fsks@fujipharma.jp](mailto:fsks@fujipharma.jp)